首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Cell chemical biology

缩写:CELL CHEM BIOL

ISSN:2451-9456

e-ISSN:2451-9448

IF/分区:7.2/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引1636
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Martin P Schwalm,Andreas Krämer,Anja Dölle et al. Martin P Schwalm et al.
The multi-step degradation process of PROteolysis TArgeting Chimeras (PROTACs) poses a challenge for their rational development, as the rate-limiting steps that determine PROTACs efficiency remain largely unknown. Moreover, the slow through...
Sabrina Fischer,Van Tuan Trinh,Clara Simon et al. Sabrina Fischer et al.
Inhibition of protein-protein interactions (PPIs) via designed peptides is an effective strategy to perturb their biological functions. The Elongin BC heterodimer (ELOB/C) binds to a BC-box motif and is essential for cancer cell growth. Her...
Yu-Xuan Liu,Shan Wan,Xiao-Qin Yang et al. Yu-Xuan Liu et al.
Metastatic colorectal cancer (mCRC) is characterized by poorer prognosis of patients and limited therapeutic approach, partly due to the lack of effective target. Using mouse models and tumor organoids, this study reported a tripartite moti...
Vitalii S Basistyi,James H Frederich Vitalii S Basistyi
In this issue of Cell Chemical Biology, Andlovic et al.1 unravel how certain fusicoccin toxins synergize with interferon-α to kill cancer cells. The results suggest that fusicoccins potentiate apoptosis by "sticking together" 14-3-3 protei...
Rui Sun,Zibo Meng,Hyeyoon Lee et al. Rui Sun et al.
Proteolysis-targeting chimeras (PROTACs) are an emerging technology for therapeutic intervention, but options to target cell surface proteins and receptors remain limited. Here we introduce ROTACs, bispecific WNT- and BMP-signaling-disabled...
Yu Zhang,Di Feng,Guanqun Mu et al. Yu Zhang et al.
RNA A-to-I editing is a post-transcriptional modification pervasively occurring in cells. Artificial intervention of A-to-I editing at specific sites of RNA could also be achieved with guide RNA and exogenous ADAR enzymes. In contrast to pr...
Matthew L Arwood,Yao Liu,Shannon K Harkins et al. Matthew L Arwood et al.
Recurrent JAK2 alterations are observed in myeloproliferative neoplasms, B-cell acute lymphoblastic leukemia, and other hematologic malignancies. Currently available type I JAK2 inhibitors have limited activity in these diseases. Preclinica...
Qian-Ming Lv,Hui-Min Lei,Shi-Yi Wang et al. Qian-Ming Lv et al.
The cGAS-STING pathway has long been recognized as playing a crucial role in immune surveillance and tumor suppression. Here, we show that when the pathway is activated in a cancer-cell-autonomous response manner, it confers drug resistance...
Sumirtha Balaratnam,Zachary R Torrey,David R Calabrese et al. Sumirtha Balaratnam et al.
Neuroblastoma RAS (NRAS) is an oncogene that is deregulated and highly mutated in cancers including melanomas and acute myeloid leukemias. The 5' untranslated region (UTR) (5' UTR) of the NRAS mRNA contains a G-quadruplex (G4) that regulate...
Andrew G McKee,Eli F McDonald,Wesley D Penn et al. Andrew G McKee et al.
Cystic fibrosis (CF) is caused by mutations that compromise the expression and/or function of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. Most people with CF harbor a common misfolded variant (ΔF508) th...